+

WO2003007869A3 - Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres - Google Patents

Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres Download PDF

Info

Publication number
WO2003007869A3
WO2003007869A3 PCT/BR2002/000099 BR0200099W WO03007869A3 WO 2003007869 A3 WO2003007869 A3 WO 2003007869A3 BR 0200099 W BR0200099 W BR 0200099W WO 03007869 A3 WO03007869 A3 WO 03007869A3
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvants
gene
codifies
gene vectors
compositions containing
Prior art date
Application number
PCT/BR2002/000099
Other languages
French (fr)
Other versions
WO2003007869A2 (en
Inventor
Silva Celio Lopes
Jose Maciel Junior Rodrigues
Original Assignee
Univ Minas Gerais
Silva Celio Lopes
Jose Maciel Junior Rodrigues
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais, Silva Celio Lopes, Jose Maciel Junior Rodrigues filed Critical Univ Minas Gerais
Priority to EP02744957A priority Critical patent/EP1420823A2/en
Priority to CA002453959A priority patent/CA2453959A1/en
Priority to AU2002317056A priority patent/AU2002317056A1/en
Publication of WO2003007869A2 publication Critical patent/WO2003007869A2/en
Publication of WO2003007869A3 publication Critical patent/WO2003007869A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to compositions which are able to stimulate an immune response in a host inoculated with an antigen of interest or the gene vector that codifies it. This composition includes microspheres based on copolymers derived from lactic acid glycolic acid encapsulating antigens, gene vectors and/or adjuvants with immunostimulatory properties obtained from mycobacterial fractions. The materialization of the present invention is the use of trehalose dimycolate associated to a heat shock protein or to the plasmid containing the gene that codifies it, encapsulated in microspheres with size smaller than 10 νm, capable of inducing specific antobodies and cellular immune responses, as well as the secretion of cytokines implicated in the protection against infectious diseases and cancer, following administration of a single dose or several doses.
PCT/BR2002/000099 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres WO2003007869A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02744957A EP1420823A2 (en) 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
CA002453959A CA2453959A1 (en) 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
AU2002317056A AU2002317056A1 (en) 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI0103887 2001-07-17
BR0103887-7A BR0103887C1 (en) 2001-07-17 2001-07-17 Immunogenic compositions containing biodegradable microspheres encapsulating antigens, gene vectors and adjuvants
BRC10103887 2002-07-04

Publications (2)

Publication Number Publication Date
WO2003007869A2 WO2003007869A2 (en) 2003-01-30
WO2003007869A3 true WO2003007869A3 (en) 2004-03-18

Family

ID=3947962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2002/000099 WO2003007869A2 (en) 2001-07-17 2002-07-17 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres

Country Status (5)

Country Link
EP (1) EP1420823A2 (en)
CN (1) CN1549728A (en)
BR (1) BR0103887C1 (en)
CA (1) CA2453959A1 (en)
WO (1) WO2003007869A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN1317560C (en) * 2005-10-19 2007-05-23 华中科技大学 A method for improving the encoding stability of quantum dot encoded microspheres
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY TARGETING FRACTIONS (AMINO ACID)
JP2011500569A (en) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー Vaccine nanotechnology
CN101376023B (en) * 2008-10-10 2011-12-28 山西海森生物制品有限公司 Vaccine sustained-release agent for birds as well as preparation and inoculation method thereof
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
PL2661253T3 (en) * 2011-01-04 2017-08-31 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
IN2014MN01594A (en) 2012-01-12 2015-05-08 Archivel Farma Sl
CN104884065B (en) * 2012-09-21 2019-01-01 强烈治疗剂公司 The method for the treatment of cancer
CN106457692B (en) 2014-05-14 2020-03-17 迪卡尔公司 Protective cover including patterned backing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207237A (en) * 1988-02-15 1989-08-21 Sawai Seiyaku Kk Tumor necrosis factor inducer
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207237A (en) * 1988-02-15 1989-08-21 Sawai Seiyaku Kk Tumor necrosis factor inducer
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 19890821, Derwent World Patents Index; AN 1989-282538 *

Also Published As

Publication number Publication date
BR0103887A (en) 2003-08-05
CN1549728A (en) 2004-11-24
CA2453959A1 (en) 2003-01-30
BR0103887C1 (en) 2005-11-08
WO2003007869A2 (en) 2003-01-30
EP1420823A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
KR970707281A (en) A polynucleotide tuberculosis vaccine
IL144671A0 (en) Immunological adjuvants compounds compositions and methods of use thereof
CA2421683A1 (en) Microparticles for delivery of the heterologous nucleic acids
PT1104306E (en) CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
Källenius et al. Should a new tuberculosis vaccine be administered intranasally?
IS4518A (en) New vaccine formulation
CA2523084A1 (en) Tuberculosis vaccine with improved efficacy
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
WO2005007673A3 (en) Immunogenic peptides
WO2015138471A1 (en) Heat inactivated poxvirus improves vaccination results
Operschall et al. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice
Peacey et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
Liu et al. The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO2005012538A3 (en) Accelerated vaccination
Li et al. The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis
Meng-Han Fish oral vaccine and mucosal immunity
WO2001010469A3 (en) Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
HK1025220A1 (en) Novel saponin compositions and uses thereof
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
Morais et al. Efficacy of Chitosan as Vaccine Adjuvant Against Paracoccidioidomycosis in Mice
Lunn Immunological basis of vaccination

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2453959

Country of ref document: CA

Ref document number: 87/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002744957

Country of ref document: EP

Ref document number: 200401274

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20028171861

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002744957

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002744957

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载